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Abstract Current combined surgical and neo-adjuvant
chemotherapy of primary metastatic osteosarcoma (OS) is
ineffective, reflected by a 5-year survival rate of affected
patients of less than 20 %. Studies in experimental OS
metastasis models pointed to the CXCR4/CXCL12 homing
axis as a novel target for OS metastasis-suppressive treat-
ment. The present study investigated for the first time the
CXCR4-blocking principle in a spontaneously metastasiz-
ing human 143B OS cell line-derived orthotopic xenograft
mouse model. The highly metastatic 143B cells, unlike the
parental non-metastatic HOS cells, express functional
CXCR4 receptors at the cell surface, as revealed in this
study by RT/PCR of gene transcripts, by FACS analysis
with the monoclonal anti CXCR4 antibody 12G5 (mAb
12G5) and by CXCL12 time- and dose-dependent stimu-
lation of AKT and ERK phosphorylation. A significantly
(p \ 0.05) higher CXCL12 dose-dependent chemotactic
response of 143B compared to HOS cells in a Boyden
chamber trans-well migration assay suggested a crucial
role of the CXCL12/CXCR4 homing axis in 143B cell lung
metastasis. Repetitive treatment of mice with 143B cell-
derived intratibial tumors given intravenous bolus injec-
tions of mAb12G5 indeed inhibited significantly (p \ 0.01)
the number of X-gal-stainable lung micrometastases of
lacZ-transduced 143B cells. Antibody treatment had also a
mild inhibitory effect on primary tumor growth associated
with remarkably less osteolysis, but it did not affect the
number of developing lung macrometastases. In conclu-
sion, these results demonstrate considerable potential of
high-affinity CXCR4-blocking agents for OS tumor cell
homing suppressive treatment in metastasizing OS com-
plementary to current (neo)-adjuvant chemotherapy.
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GAPDH Glyceraldehyde-3-phosphate dehydrogenase
FACS Fluorescence-activated cell sorting
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Introduction
Osteosarcoma (OS) is the most common primary bone
neoplasia in children and young adolescents [1]. It has an
incidence of 3 persons per million and year and a median
peak at 16 years [2]. Multi-agent chemotherapy resulted in
disease-free survival of 60–70 % of the patients with
localized disease [3]. These improvements made limb
sparing surgery possible in 85–90 % of the cases without
compromising the outcome compared to amputation [4].
Despite this progress for patients with localized disease,
patients with metastases still have a very low mean 5-year
survival rate of approximately 20 % [5–7]. The low sur-
vival rate of patients with metastatic disease is in part
related to the fact that, until now, effective treatment
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targeting clinically non-detectable micro-metastases does
not exist [8, 9]. Consequently, these non-treatable metas-
tases eventually grow to life-threatening lung nodules with
a fatal outcome.
Metastasis is a complex multistep process that includes
local tissue invasion of metastatic cells, their survival in the
circulation, ‘‘homing’’ to and extravasation in a secondary
organ and proliferation/growth at the metastatic sites [10,
11]. Chemokines interacting with chemokine receptors
expressed by metastasizing tumor cells have crucial roles
in directing migrating cells towards secondary organs. This
is well documented for the chemokine CXCL12 and the
chemokine receptor CXCR4. Mueller and co-workers ini-
tially postulated and discovered the CXCL12–CXCR4
homing axis in cancer metastasis [12, 13]. They demon-
strated that CXCR4 expressing breast cancer cells prefer-
entially migrated towards protein extracts of the lung,
which expresses CXCL12 abundantly. Chemo-attraction by
lung tissue extracts was abolished by CXCL12-neutralizing
antibodies and by preincubation of breast cancer cells with
CXCR4-blocking antibodies. Meanwhile, CXCL12 and
CXCR4 were found to be instrumental for the development
and progression of numerous different cancer types of
epithelial, haematopoietic or mesenchymal origin [14–17].
It is noteworthy that, in normal physiology, CXCL12 and
CXCR4 are important for the development of the CNS, the
heart and the immune system. Moreover, they are involved
in angiogenesis and stem cell trafficking and in prolifera-
tion and apoptosis.
At the cellular level, binding of CXCL12 to CXCR4 was
shown to stimulate intracellular calcium flux, to activate
AKT and ERK signaling pathways, and to up-regulate the
formation of focal adhesions, which ultimately results in
increased migration along gradients of locally expressed
and secreted chemokines [18–20].
In OS patients, overall disease-free and metastasis-free
survival was found to be inversely related to the expression
of CXCR4-encoding mRNA in primary tumor tissue [21].
Furthermore, a tissue microarray analysis showed that
CXCR4 expression correlated significantly with the
expression of VEGF and that co-expression of CXCR4/
VEGF was an indicator for poor patient survival [22, 23].
Experimentally, proof of principle studies demonstrated
that inhibition of CXCL12-evoked CXCR4 signaling by
respective blocking agents inhibited metastasis in experi-
mental models, achieved by intravenous tumor cell injec-
tion [24–26]. However, these models did not reproduce
most of the complex processes characteristic for the met-
astatic cascade.
Consequently, we reinvestigated in the present study the
metastasis suppressive potential of the CXCR4 blocking
principle in a human 143B OS cell line-derived spontane-
ously metastasizing intratibial OS mouse model that
closely mimics the human disease [27]. Primary intratibial
tumors were provoked by injection of highly metastatic
human 143B OS cells stably transduced with a constitu-
tively expressed lacZ gene (143B-lacZ cells). This allowed
post-mortem X-gal staining of primary tumor tissue and,
more importantly, of lung metastases down to the single
cell level as reported [28]. Tumor-bearing mice were
treated at 4-day intervals by tail-vein bolus injections of the
monoclonal anti-CXCR4 antibody (mAb 12G5), known to
block the binding of CXCL12 to CXCR4 and to inhibit
CXCL12-evoked chemotaxis in vitro [29, 30]. Tumor-
bearing mice injected with control mouse IgG were con-
sidered as untreated controls. CXCR4 antibody treatment
inhibited 143B-lacZ cell homing to the lung and had a mild
inhibitory effect on primary tumor osteolysis and growth
[31, 32]. Thus, the results of the present study demonstrate
for the first time efficacy of the metastasis suppressive
CXCR4 blocking principle in an orthotopic, spontaneously
metastasizing OS model that mimics most aspects of the
human disease.
Materials and methods
Cell lines
HOS cells were purchased from the American type culture
collection (Rockville, MD) and 143B cells from the
European collection of cell cultures (Salisbury, UK) [31].
Both cell lines were grown in Dulbecco’s modified Eagle
medium (DMEM) (4.5 g/L glucose) and Ham F12 (F12)
medium (1:1) supplemented with 2 mM L-glutamine and
10 % fetal calf serum (FCS) (GIBCO, Basel, Switzerland)
(cell culture medium) in a humidified atmosphere of 95 %
air and 5 % CO2 at 37 C.
RNA isolation, reverse transcription (RT),
and polymerase chain reaction (PCR)
Total RNA was isolated from individual cell lines with
TriReagent (Sigma-Aldrich, St Louis, MO) according to
the manufacturer’s protocol. The RNA was quantified by
measuring the absorption of extracts at 260 nm. The
integrity of the RNA was assessed by agarose gel-elec-
trophoresis. The expression levels of mRNA encoding
CXCR4 were determined by semi-quantitative RT/PCR
with Gapdh transcripts as a reference. cDNA was synthe-
sized from 1 lg of total RNA with the High Capacity
cDNA reverse transcription kit (Applied Biosystems Inc.,
Foster City, CA) and the protocol recommended by the
supplier. PCR reactions of 50 ll final volume contained 1X
PCR buffer, 0.4 ll of the RT reaction, 1.25 U Taq poly-
merase (5Prime), each dNTP at 200 lM concentration, and
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forward and reverse primers specific for GAPDH (For-
ward: 50-TGA ACG GGA AGC TCA CTG GCA TGG -30;
Reverse: 50-TGG GTG TCG CTG TTG AAG TCA GAG
GA GA-30) and for CXCR4 (Forward: 50- GAG TGC TCC
AGT AGC CAC CGC ATC-30; Reverse: 50-TCC GTC
ATG CTT CTC AGT TTC TTC TGG-30) encoding cDNA
at 0.2 lM concentration. After initial denaturation at 94 C
for 3 min, cDNA was amplified by 27 (GAPDH) or 40
(CXCR4) PCR-cycles (denaturation at 94 C for 40 s,
primer pair-dependent annealing at 67 C (GAPDH) or
69 C (CXCR4) for 40 s, and elongation at 72 C for 20 s)
followed by final elongation at 72 C for 7 min. PCR
products were analyzed by agarose gel electrophoresis.
FACS analysis of CXCR4 expression
HOS and 143B cells grown to 50 % confluence were
detached with MACS buffer (PBS, 0.05 % ethylenedia-
minetetraacetic acid (EDTA) and 2 % FCS). They were
then transferred to 5 ml Polystyrene FACS tubes (BD
FALCONTM, Franklin Lakes, NJ, USA) collected by cen-
trifugation at 1,600 rpm and 4 C for 5 min and resus-
pended. Subsequently, the cells were incubated with
5 lg/ml of CXCR4 antibody, clone 12G5 (R&D System,
Abingdon, UK), at 4 C for 30 min. The cells were then
washed twice with PBS and incubated at 4 C for 20 min
with 5 lg/ml of Alexa-conjugated goat anti-mouse IgG
(Invitrogen, Carlsbad, CA). The cells were again washed
twice with PBS and filtered through PARTEC CELL
TRICS filters (50 lm pore size, Go¨rlitz, Germany). The
percentage of cells expressing CXCR4 at the cell surface
was determined with a FACS Aria/Calibur device (Beckton
Dickinson, Allschwil, Switzeland).
Analysis of CXCR4 signaling on Western Blots
Cells were grown to 80 % confluence and starved over-
night in serum-free RPMI 1640 medium supplemented
with 0.1 % BSA (Sigma-Aldrich, St Louis, MO). The next
day, the cells were detached (PBS with 0.05 % EDTA),
washed with PBS and stimulated in suspension with
100 ng/ml (12.5 nM) human recombinant CXCL12 (R&D
System, Abingdon, UK) at 37 C for indicated time peri-
ods. Incubations were stopped by the addition of ice-cold
PBS. Cells were then collected by centrifugation and lysed
on ice for 45 min in buffer containing NaF, orthovanadate
and protease inhibitors (Roche, Basel, Switzerland). Cell
lysates were cleared by centrifugation and mixed with an
equal volume of 2 9 Laemmli sample buffer and incu-
bated at 95 C for 5 min. Proteins were separated by SDS-
PAGE and transferred to nitrocellulose membranes. Phos-
pho(p)-AKT, total AKT, p-ERK and total ERK were
detected by incubation at 4 C overnight with respective
primary antibodies (Cell Signalling Technology Inc.,
Denver, MA) followed by incubation at RT for 1 h with
secondary horseradish peroxidase conjugated anti-rabbit
IgG (Santa Cruz Biotechnology Inc., Heidelberg, Ger-
many). The proteins were then visualized with Immobilon
chemiluminescence substrate (Millipore, Billerica) and
quantified with a VersaDocTM Imaging System (Bio-Rad
Laboratories, Munich, Germany). Antibody blocking
experiments were essentially performed like the stimula-
tion experiments described above, except that 143B and
HOS cells were kept adherent and pre-incubated 300 with
either 20 lg (ml non-specific IgG (Jackson Immuno
Research Rheinfeld, Switzerland) or 20 lg/ml of the highly
specific 12G5 (anti-CXCR4) (R&D System, Abingdon,
UK), before stimulating for 100 with 100 ng/ml SDF-1.
Chemotaxis assay
Chemotaxis assays were performed in triplicates in 48-well
Boyden chambers (NeuroProbe, Gaithersburg, MD) with
polyvinylpyrrolidone-free polycarbonate membranes of
8 lm pore size. Cells grown to 50 % confluence were
harvested and resuspended in chemotaxis medium com-
posed of DMEM and F12 medium (1:1) supplemented with
2 mM L-glutamine and 0.2 % FCS. 29104 cells in 50 lL
chemotaxis medium were then added to the upper chamber
of each well. Chemotaxis medium containing indicated
concentrations of CXCL12 was added to the bottom
chamber and chemotaxis was allowed under cell culture
conditions for 4 h. Cells adhering to the upper surface of
the membrane were removed with a rubber policeman.
Cells that had migrated through the filter and adhered to the
lower surface of the membrane were fixed and stained with
Diff-Quik (Medion Diagnostics AG, Du¨dingen Switzer-
land). They were counted under the microscope in five
randomly selected fields at 100-fold magnification.
LacZ gene transduction of OS cell lines
Retroviral particles for stable lacZ gene transduction (lacZ-
retrovirus) of OS cell lines were prepared as reported [28].
HOS and 143B cells were grown to subconfluence and
infected with lacZ-retrovirus by incubation for 2 h with
1 ml virus-containing medium supplemented with 8 lg/ml
polybrene (Sigma-Aldrich, St Louis, MO). The cells were
then cultured for 7 days in medium containing 1,200 lg/ml
G-418 (Invitrogen, Carlsbad, CA). Selection of lacZ
transduced HOS (HOS-lacZ) and 143B (143B-lacZ) cells
was monitored over time in aliquots of cells fixed with 4 %
formaldehyde for 20 min and then stained with X-gal at
37 C overnight.
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CXCR4 antibody treatment of SCID mice
with intratibial 143B/lacZ cell-derived OS
Female 6–8 week old severe combined immunodeficient
(SCID) were purchased from Charles River Laboratories
(Sulzfeld, Germany) and maintained under OHB condi-
tions. Animal care and experimental procedures were in
accordance with institutional guidelines and approved by
the Ethics Committee of the Veterinary Department, Can-
ton of Zurich, Switzerland (License Number 169/2009).
143B-lacZ cells were grown to subconfluence, detached
with Trypsin/PBS/0.05 % EDTA and resuspended in PBS/
0.05 % EDTA. The single cell suspension contained 5x107
cells/ml. Ten microliter aliquots of the cell suspension
equivalent to 5x105 cells were orthotopically injected into
the medullar cavity of the left tibia of individual mice.
After tumor cell injection, the mice were randomly divided
into two groups. Treatment was initiated on the day of
tumor cell injection and continued in 4-day intervals by
bolus tail-vein injections of 100 ll PBS containing 200 lg
mouse IgG (Jackson Immuno Research Rheinfeld, Swit-
zerland) (control group) or 200 lg CXCR4 12G5-
antibodies (treatment group). Tumor development and
osteolysis were monitored by X-ray once a week. Tumor
volume was calculated from caliper rule measurements of
the width and the length of the tumor-bearing tibia using
the following formulas: leg volume = length x (width)2 x
0.5; tumor volume = leg Volume on day X – leg Volume
on day 0; (X = 0, 4, 12, 16 and 20 days after tumor cell
injection). All mice were sacrificed on experimental day 20
and the organs were prepared as reported [30]. Lungs were
further prepared as previously reported [28, 33]. lacZ gene
expressing metastatic tumor cells were visualized by X-
Gal staining as described [34]. Briefly, lung tissue was
refixed with 2 % formaldehyde and 0.2 % glutaraldehyde
in PBS at room temperature for 1 h, washed 3 times with
PBS and then stained in X-Gal solution at 37 C for at least
3 h.
Micrometastases, defined as indigo-blue stained foci
smaller than 0.1 mm in diameter and macrometastases,
defined as indigo-blue stained foci larger than 0.1 mm in
diameter, on the surface of whole-mounts of lungs, were
counted. Indigo-blue stained foci were counted on the
surface of whole-mounts of lungs.
Fig. 1 Expression of CXCR4
in the parental low metastatic
human osteosarcoma HOS cell
line and the highly metastatic
143B subline. a semi-
quantitative RT/PCR analysis of
Cxcr4 and Gapdh (reference)
transcript levels in total RNA
isolated from 50 % (a) and
100 % (b) confluent cells,
M marker lanes. b FACS
analysis of indicated cell lines
processed for cell surface
immunostaining of CXCR4 in
the absence (control) or
presence (CXCR4?) of primary
12G5 CXCR4 antibodies
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Statistical analysis
Results are presented as mean ± standard error of the
mean (SEM). The values of the primary tumor volume and
the numbers of metastases were transformed to a loga-
rithmic scale before they were analyzed for significance by
2-way ANOVA test with GraphPad Prism 5.01 software.
Results
Expression and signaling of CXCR4 in HOS and 143B
cells
Semi-quantitative RT/PCR analysis of total RNA extracted
from 50 % to 100 % confluent HOS and 143B cells
Fig. 2 Time-dependent
stimulation of AKT and ERK
phosphorylation by CXCL12 in
HOS and 143B cells. a, b
western blot analysis of extracts
of HOS (a) and of 143B (c) cells
incubated with 12.5 nM
CXCL12 for indicated time
periods. The levels of p-AKT
and of total AKT (left panels)
and of p-ERK and of total ERK
(right panels) are shown. Data
shown in a and c are
representative for at least 3
independent experiments. b, d
Quantitative analysis of the
time-dependent stimulation of
AKT (left) and ERK (right)
phosphorylation in HOS
(b) and143B (d) cells; Data
indicate mean ± SEM (n = 3)
levels of p-AKT and p-ERK
normalized to total AKT and
total ERK, respectively, at
indicated time points;
*p B 0.05 compared to control
(C)
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detected only trace amounts of CXCR4-encoding tran-
scripts in HOS cells compared to those observed in 143B
cells (Fig. 1a). These results were in good agreement with
the expression of CXCR4 on the surface of HOS and 143B
cells analyzed by FACS (Fig. 1b). CXCR4 cell surface
immunostaining was only recognized in 3 ± 1 % of the
HOS cells analyzed, whereas 75 ± 5 % of the 143B cells
expressed immune-detectable CXCR4 at the cell surface.
This pattern of CXCR4 expression in HOS and 143B cells
was confirmed by the signaling response of the cells to
CXCL12. Time-dependent transient phosphorylation of AKT
and ERK upon stimulation with 100 ng/ml CXCL12 was only
observed in 143B cells (Fig. 2c). Maximal stimulation was
observed after 10 min of incubation with CXCL12 and
amounted to a 22- and 2-fold increase of phospho-AKT and
phospho-ERK, respectively, over basal levels when normal-
ized to total AKT and ERK (Fig. 2d). HOS cells did not show
any significant increase in phosphorylation of AKT and ERK
when compared to the control cells after normalization to total
AKT and ERK (Fig. 2a, b). CXCR4 dependent AKT signaling
could by efficiently blocked in 143B cells by 12G5 while HOS
did not show any stimulation and consequently any inhibition
upon pre-incubation with 12G5 (Fig. 3a, b).
CXCL12-provoked chemotaxis of HOS and 143B cells
Migratory activity of the cell lines, considered as an
in vitro indicator of in vivo metastatic activity, was
Fig. 3 AKT signaling
inhibition by the blocking anti-
CXCR4 antibody 12G5 in 143B
and HOS cells. Shown are
p-AKT and total AKT levels in
HOS (a) and 143B (b) cells that
were left untreated (ctr) or
stimulated 10 min with SDF-1
(100 SDF-1) and were pre-
incubated with IgG (ctr ? IgG
and 100 SDF-1 ? IgG) or 12G5
(ctr ? 12G5 and 100 SDF-
1 ? 12G5) antibodies. Data
indicate mean ± SEM (n = 3)
levels of p-AKT normalized to
total AKT (*p B 0.05 compared
to control 100 SDF-1
stimulation)
Fig. 4 CXCL12 dose-dependent CXCR4-mediated chemotaxis of
HOS and 143B cells. Cells were seeded in 48-well Boyden chambers
on membranes of 8 lm pore size and chemotaxis to indicated
concentrations of CXCL12 added to the medium in the bottom
chamber was allowed for 4 h. Non-migrating cells adhering to the
upper surface of the membrane were removed and cells that had
migrated across the membrane and adhered to the bottom surface
were fixed, stained with Diff Quick and counted under the
microscope. *p B 0.05 compared to 143B cells incubated in the
absence of CXCL12; #p B 0.05 compared to HOS cells in the absence
of CXCL12
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assessed in a Boyden chamber migration assay in the
absence and presence of CXCL12 in the lower chamber.
The basal motility, indicated by the number of cells
migrating across the filter in the absence of CXCL12, was
15-times higher in 143B than in HOS cells (Fig. 4). A
maximal 3.7-fold increase in the number of migrating 143B
cells in response to 1 lg/mL CXCL12 in the lower com-
partment of the Boyden chamber reflected the expected
chemotactic response. HOS cells with only hardly detect-
able CXCR4 expression, on the other hand, showed only a
minimal chemotactic response to CXCL12.
Altogether, the findings were consistent with the
reported high metastatic activity of 143B compared to HOS
cells and suggested that the CXCL12-stimulated CXCR4
signaling and migration activity of 143B cells contributed
to their in vivo metastatic potential. Thus, the mAb 12G5 to
human CXCR4, reported to inhibit the binding of human
CXCL12 and downstream signaling of human CXCR4,
was used to investigate the CXCR4 blocking principle in
the 143B-lacZ cell-derived intratibial, spontaneously
metastasizing OS mouse model, mimicking the human
condition.
Repetitive systemic treatment of SCID mice suffering
from intratibial 143B-lacZ OS xenografts with CXCR4-
blocking antibodies diminishes osteolysis and inhibits
lung micro-metastasis
Osteolysis in the proximal tibia, visualized by X-ray before
sacrifice of the mice on day 20 after 143B-lacZ cell
injection, was considerably less pronounced in animals
treated in 4-day intervals by tail–vein injections of 200 lg
mAb 12G5 compared to mice receiving the same doses of
control mouse IgG (Fig. 5a). Mice treated with mAb 12G5
showed also a tendency (p = 0.052) to tumors with a
smaller volume than those of control mouse IgG-treated
animals (Fig. 5b). Thus, repetitive tail-vein bolus injection
of CXCR4 antibodies inhibited the development of OS in
the tibia from 143B-lacZ xenografts during the experi-
mental period of 20 days. The ex vivo analysis of the X-gal
stained metastatic lesions on lung surfaces showed that the
repetitive treatment of the mice with mAb 12G5 compared
to the treatment with control IgG had no effect on the
number of outgrown lung macrometastases ([0.1 mm in
diameter) at sacrifice on day 20 after intratibial tumor cell
injection (Fig. 6a). However, mice treated with mAb 12G5
had significantly (p \ 0.01) lower numbers of apparently
minimally growing micro-metastases (\0.1 mm in diame-
ter) than mice treated with mouse IgG (Fig. 6b), indicating
that circulating CXCR4-blocking antibodies effectively
inhibited the homing to the lung of 143B-lacZ cells dis-
seminating from primary intratibial tumors.
Discussion
Metastasis predominantly to the lung remains the leading
cause of death in OS patients despite the implementation of
neoadjuvant/adjuvant chemotherapy in the late 1970s [7].
Consequently, new treatment modalities targeting the
complex metastatic process are needed. The chemokine
CXCL12 has been recognized as an important chemoat-
tractant of CXCR4 expressing metastasizing cells of
numerous tumor types. CXCL12 has also been proposed as
molecular cue guiding metastasizing OS cells to the lung
where CXCL12 is expressed [12, 21, 35, 36]. Studies in OS
mouse models of experimental metastasis, revealed by
intravenous injections of tumor cells, indeed demonstrated
Fig. 5 Effects of repetitive systemic administration of 12G5 CXCR4-
blocking antibodies on intratibial primary tumor development of
143B-lacZ osteosarcoma cell xenografts. a Representative X-ray
images of 143B-lacZ cell-derived tumors in severe combined
immunodeficient mice treated with control mouse IgG (top panels)
or with 12G5 CXCR4 antibodies (bottom panels). b Primary tumor
volumes calculated from caliper measurements of tumor bearing
tibiae in control mouse IgG- or 12G5 antibody-treated mice. The
results are from two independent experiments with 7 (first experi-
ment) and 6 (second treatment) (open triangle) and 9 (filled circle)
mice per indicated group
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the relevance of the CXCL12/CXCR4 axis in OS metas-
tasis [24–26]. These were seminal and valuable proof of
principle studies despite the fact that they employed mouse
models of experimental metastasis, which rather incom-
pletely reproduce the complex cascade of biological pro-
cesses that are crucial in OS metastasis. In the present
Fig. 6 Micrometastasis-
inhibiting effects of repetitive
administration of CXCR4-
blocking 12G5 antibodies in
mice with intratibial 143B-lacZ
cell-derived tumors.
a Representative images of
whole mounts of lungs of mice
treated with mouse IgG (left) or
with 12G5 CXCR4 antibodies
(right). X-gal stained metastases
appear in blue. b Microscopic
images of representative areas
of lung whole mounts (4-fold
magnification, size
bar = 10 lm) of 143B-lacZ cell
tumor-bearing mice treated with
mouse IgG (left) or with 12G5
CXCR4 antibodies (right).
Arrows point to X-gal-stained
micrometastases in blue. The
total numbers of
micrometastases per lung of
indicated mice treated with
mouse IgG or with 12G5
antibodies are shown in the
bottom panel. The results were
obtained in two independent
experiments with 7 (open
triangle) and 9 (filled circle)
mice per indicated group.
p \ 0.01 was considered as
statistically significant
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study, we therefore reinvestigated the CXCR4-blocking
principle for OS treatment in the human 143B OS cell line-
derived intratibial xenograft model in SCID mice that
closely mimics the human disease with metastasis from the
primary bone tumor to the lung.
The results presented here demonstrate that targeting the
CXCL12/CXCR4 axis in the orthotopic mouse model of
spontaneously metastasizing OS by repetitive tail-vein
bolus injections of the anti-CXCR4 mAb 12G5 slowed
down the osteolytic tumor development and, even more
importantly in the context of OS, significantly reduced the
number of primary tumor cells that disseminated to the
lung where they were recognized as apparently non-
growing micrometastases. This is an important finding in
view of urgently needed novel strategies for more effective
treatment of OS patients with metastatic disease. Bruland
and co-workers could further demonstrate that the number
of circulating micro-metastasis positively correlated with
OS patient outcome [37] underlining the importance of
finding efficient treatment modalities against these circu-
lating cells as shown in the present study. However, the
applied antibody treatment did not significantly affect the
number of outgrowing lung macro-metastases. These
observations likely reflect some limitations of the here used
experimental OS mouse model, which is dependent on
intratibial injection of the highly aggressive metastatic
143B OS cells. Despite taking any possible measures to
avoid the escape of tumor cells from the injection site, we
believe that it is almost inevitable that a small number of
injected cells end up in the circulation and finally grow as
metastases in the lung before effective onset of the anti-
body therapy. In an attempt to minimize the consequences
of the above mentioned cell leakage and to further estimate
the full potential of the herein presented antibody therapy
strategy an upfront study administrating antibody prior to it
cell injection is foreseeable. The evident disadvantage of
such a treatment modality would be its lack of reflection of
the patient situation. Moreover, in interpreting the data, it
also has to be considered that approximately 25 % of 143B
cells analyzed by FACS before injection showed at least
temporarily non-detectable CXCR4 expression at the cell
surface, and it is conceivable that such cells were ineffi-
ciently targeted by CXCR4 antibodies. Nevertheless, the
number of lung micro-metastases was significantly reduced
by antibody treatment, indicating that the CXCR4-blocking
antibody 12G5 effectively interfered with the homing of
metastasizing 143B cells to the lung, most likely through
binding to the cells in the circulation. In addition we could
show that the anti-CXCR4 antibody 12G5 efficiently
blocked CXCL12 dependent AKT signaling, involved in
migration and cell survival, essential for metastatic spread,
in the highly metastatic human OS cells 143B, but not in
their parental non-metastatic HOS cells which lack CXCR4
and are therefore unresponsive towards CXCL12. Inter-
estingly, the metastasis inhibiting potential of mAb12G5
treatment observed in the present study was comparable to
that reported for a tumor challenging experiment per-
formed by Bertolini and co-workers [38]. In this report
human Non-Hodgkin’s Lymphoma cells, pre-treated with
mAb 12G5, were tail- vein injected into immunocompro-
mised NOD/SCID mice and animals having received
antibody-treated cells showed a significantly longer sur-
vival compared to control animals. In the same study
diminished primary tumor development was observed at a
moderate level, which is in agreement with the findings of
the present study. Thus, all these observations taken toge-
ther suggest, that, in the present study, tail-vein adminis-
tered CXCR4 antibodies most effectively interfered with
CXCL12-guided metastasizing, CXCR4 expressing 143B
cells in the circulation. Furthermore we cannot exclude that
also other mechanisms like 12G5 mediated ADCC (anti-
body dependent cellular cytotoxicity) via monocyte/mac-
rophages or NK cells lead to cancer cell killing in the
bloodstream. There the cells were likely exposed to the
temporarily highest concentrations of the antibodies on
their way to the lungs. In the developing primary bone
tumor and in growing metastases in the lung, on the other
hand, the antibodies likely had poor access to the tumor
cells due to slow and inefficient delivery mechanisms in
these tissues for proteins of that size. Consequently, the
growth of tumor cells in the bone and in lung metastases
was much less effectively inhibited by CXCR4 antibodies
than CXCL12-guided and CXCR4-mediated chemotaxis of
metastasizing tumor cells in the circulation.
In conclusion, the results of the present study demon-
strate that a metastasis-suppressive CXCR4-blocking
strategy is effective in an intratibial mouse model of
spontaneously metastasizing, CXCR4-expressing OS.
Consequently, the development of high affinity CXCR4-
blocking agents with a long half-life and in formulations
suitable for selective targeting of metastasizing OS cells in
the primary tumor, the circulation and secondary organs
appears to be a worthwhile approach to increase the effi-
cacy of the treatment of metastasizing OS in combination
with current treatment modalities or novel drugs.
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